Outcomes and prognostic factors for women with breast cancer in Malawi.


Journal

Cancer causes & control : CCC
ISSN: 1573-7225
Titre abrégé: Cancer Causes Control
Pays: Netherlands
ID NLM: 9100846

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 25 07 2019
accepted: 18 02 2020
pubmed: 4 3 2020
medline: 1 7 2020
entrez: 4 3 2020
Statut: ppublish

Résumé

Breast cancer incidence in sub-Saharan Africa (SSA) is increasing, and SSA has the highest age-standardized breast cancer mortality rate worldwide. However, high-quality breast cancer data are limited in SSA. We examined breast cancer patient and tumor characteristics among women in Lilongwe, Malawi and evaluated risk factor associations with patient outcomes. We consecutively enrolled 100 women ≥ 18 years with newly diagnosed, pathologically confirmed breast cancer into a prospective longitudinal cohort with systematically assessed demographic data, HIV status, and clinical characteristics. Tumor subtypes were further determined by immunohistochemistry, overall survival (OS) was estimated using Kaplan-Meier methods, and hazards ratios (HR) were calculated by Cox proportional hazard analyses. Of the 100 participants, median age was 49 years, 19 were HIV-positive, and 75 presented with late stage (III/IV) disease. HER2-enriched and triple-negative/basal-like subtypes represented 17% and 25% tumors, respectively. One-year OS for the cohort was 74% (95% CI 62-83%). Multivariable analyses revealed mortality was associated with HIV (HR, 5.15; 95% CI 1.58-16.76; p = 0.006), stage IV disease (HR, 8.86; 95% CI 1.07-73.25; p = 0.043), and HER2-enriched (HR, 7.46; 95% CI 1.21-46.07; p = 0.031), and triple-negative subtypes (HR, 7.80; 95% CI 1.39-43.69; p = 0.020). Late stage presentation, HER2-enriched and triple-negative subtypes, and HIV coinfection were overrepresented in our cohort relative to resource-rich settings and were associated with mortality. These findings highlight robust opportunities for population- and patient-level interventions across the entire cascade of care to improve breast cancer outcomes in low-income countries in SSA.

Sections du résumé

BACKGROUND BACKGROUND
Breast cancer incidence in sub-Saharan Africa (SSA) is increasing, and SSA has the highest age-standardized breast cancer mortality rate worldwide. However, high-quality breast cancer data are limited in SSA.
MATERIALS AND METHODS METHODS
We examined breast cancer patient and tumor characteristics among women in Lilongwe, Malawi and evaluated risk factor associations with patient outcomes. We consecutively enrolled 100 women ≥ 18 years with newly diagnosed, pathologically confirmed breast cancer into a prospective longitudinal cohort with systematically assessed demographic data, HIV status, and clinical characteristics. Tumor subtypes were further determined by immunohistochemistry, overall survival (OS) was estimated using Kaplan-Meier methods, and hazards ratios (HR) were calculated by Cox proportional hazard analyses.
RESULTS RESULTS
Of the 100 participants, median age was 49 years, 19 were HIV-positive, and 75 presented with late stage (III/IV) disease. HER2-enriched and triple-negative/basal-like subtypes represented 17% and 25% tumors, respectively. One-year OS for the cohort was 74% (95% CI 62-83%). Multivariable analyses revealed mortality was associated with HIV (HR, 5.15; 95% CI 1.58-16.76; p = 0.006), stage IV disease (HR, 8.86; 95% CI 1.07-73.25; p = 0.043), and HER2-enriched (HR, 7.46; 95% CI 1.21-46.07; p = 0.031), and triple-negative subtypes (HR, 7.80; 95% CI 1.39-43.69; p = 0.020).
CONCLUSION CONCLUSIONS
Late stage presentation, HER2-enriched and triple-negative subtypes, and HIV coinfection were overrepresented in our cohort relative to resource-rich settings and were associated with mortality. These findings highlight robust opportunities for population- and patient-level interventions across the entire cascade of care to improve breast cancer outcomes in low-income countries in SSA.

Identifiants

pubmed: 32124187
doi: 10.1007/s10552-020-01282-4
pii: 10.1007/s10552-020-01282-4
pmc: PMC7115156
mid: NIHMS1570820
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

393-402

Subventions

Organisme : Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
ID : P30CA016086
Organisme : University of North Carolina at Chapel Hill
ID : R24TW008927
Organisme : FIC NIH HHS
ID : R24 TW008927
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA190152
Pays : United States
Organisme : NCI NIH HHS
ID : P20 CA210285
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016086
Pays : United States
Organisme : NCI NIH HHS
ID : P50CA058223
Pays : United States
Organisme : NCHHSTP CDC HHS
ID : U2G PS001965
Pays : United States
Organisme : Malawi Cancer Consortium and Regional Center of Excellence for NCDs
ID : U54CA190152, P20CA210285
Organisme : Center for AIDS Research, University of North Carolina at Chapel Hill
ID : P30AI050410
Organisme : FIC NIH HHS
ID : D43 TW009340
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI050410
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA058223
Pays : United States
Organisme : FIC NIH HHS
ID : D43TW009340
Pays : United States

Références

BMC Res Notes. 2012 Mar 16;5:149
pubmed: 22424105
Int J Cancer. 2017 Aug 15;141(4):694-700
pubmed: 28493322
Breast J. 2015 Nov-Dec;21(6):627-33
pubmed: 26547900
J Clin Oncol. 2015 Jul 20;33(21):2376-83
pubmed: 26077242
J Natl Cancer Inst. 2018 Sep 1;110(9):959-966
pubmed: 29529223
AIDS. 2012 Jul 31;26 Suppl 1:S19-30
pubmed: 22781175
AIDS. 2013 Nov 28;27(18):2933-42
pubmed: 23921614
J Glob Health. 2018 Jun;8(1):010419
pubmed: 29740502
J Clin Oncol. 2009 Sep 20;27(27):4515-21
pubmed: 19704069
Patient Educ Couns. 2017 Jan;100(1):167-173
pubmed: 27528411
J Glob Oncol. 2016 Jul 27;2(5):302-310
pubmed: 28717716
Int J Cancer. 2014 Nov 1;135(9):2173-82
pubmed: 24658866
Breast J. 2002 Jul-Aug;8(4):234-43
pubmed: 12100117
Ann Oncol. 2013 Sep;24(9):2206-23
pubmed: 23917950
JAMA. 2017 Jan 3;317(1):37-47
pubmed: 27918780
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27
pubmed: 26667886
Arch Pathol Lab Med. 2010 Jun;134(6):907-22
pubmed: 20524868
Breast Cancer Res. 2013;15(5):R84
pubmed: 24041225
PLoS One. 2015 Aug 12;10(8):e0135602
pubmed: 26267867
PLoS Med. 2010 May 25;7(5):e1000279
pubmed: 20520800
Breast Cancer Res Treat. 2017 Nov;166(2):351-365
pubmed: 28776284
J Glob Oncol. 2018 Sep;4:1-11
pubmed: 30241185
World J Surg Oncol. 2018 Mar 22;16(1):63
pubmed: 29566711
J Clin Oncol. 2007 Jan 1;25(1):118-45
pubmed: 17159189
Pan Afr Med J. 2014 Apr 05;17:249
pubmed: 25309649
Histopathology. 1991 Nov;19(5):403-10
pubmed: 1757079
J Womens Health (Larchmt). 2010 Dec;19(12):2261-6
pubmed: 20950138
PLoS Med. 2014 Sep 09;11(9):e1001720
pubmed: 25202974
Nat Med. 2015 Oct;21(10):1128-38
pubmed: 26444637
Cancer Causes Control. 2017 Feb;28(2):137-143
pubmed: 28097471
CMAJ Open. 2017 Sep 25;5(3):E734-E739
pubmed: 28951445
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Ghana Med J. 2012 Mar;46(1):8-13
pubmed: 22605883
Curr Opin HIV AIDS. 2017 Jan;12(1):69-76
pubmed: 27849632
Int J Cancer. 2018 Apr 15;142(8):1568-1579
pubmed: 29197068
PLoS One. 2013 Aug 07;8(8):e70361
pubmed: 23950924
J Natl Cancer Inst. 2014 Apr 28;106(5):
pubmed: 24777111
Breast. 2011 Aug;20(4):303-8
pubmed: 21641801
Oncol Rev. 2019 Jan 14;13(1):376
pubmed: 30713605
Eur J Cancer. 2018 Apr;93:19-27
pubmed: 29448072

Auteurs

Victoria M Youngblood (VM)

UNC-Project Malawi, Private Bag A-104, Lilongwe, Malawi.
University of North Carolina At Chapel Hill, Chapel Hill, USA.

Ruth Nyirenda (R)

Kamuzu Central Hospital, Lilongwe, Malawi.

Richard Nyasosela (R)

Kamuzu Central Hospital, Lilongwe, Malawi.

Takondwa Zuze (T)

UNC-Project Malawi, Private Bag A-104, Lilongwe, Malawi.

Yi Yang (Y)

Aventura Hospital, Aventura, USA.

Evaristar Kudowa (E)

UNC-Project Malawi, Private Bag A-104, Lilongwe, Malawi.

Agnes Moses (A)

Partners in Hope, Lilongwe, Malawi.

Jennifer Kincaid (J)

UNC-Project Malawi, Private Bag A-104, Lilongwe, Malawi.
Thomas Jefferson University, Philadelphia, USA.

Chifundo Kajombo (C)

Kamuzu Central Hospital, Lilongwe, Malawi.

Coxcilly Kampani (C)

UNC-Project Malawi, Private Bag A-104, Lilongwe, Malawi.

Fred Chimzimu (F)

UNC-Project Malawi, Private Bag A-104, Lilongwe, Malawi.

Maurice Mulenga (M)

Kamuzu Central Hospital, Lilongwe, Malawi.

Chrissie Chilima (C)

UNC-Project Malawi, Private Bag A-104, Lilongwe, Malawi.

Grace K Ellis (GK)

UNC-Project Malawi, Private Bag A-104, Lilongwe, Malawi.

Ryan Seguin (R)

UNC-Project Malawi, Private Bag A-104, Lilongwe, Malawi.

Maganizo Chagomerana (M)

UNC-Project Malawi, Private Bag A-104, Lilongwe, Malawi.
University of North Carolina At Chapel Hill, Chapel Hill, USA.

Rebecca Maine (R)

UNC-Project Malawi, Private Bag A-104, Lilongwe, Malawi.
University of North Carolina At Chapel Hill, Chapel Hill, USA.

Sheryl Jordan (S)

UNC-Project Malawi, Private Bag A-104, Lilongwe, Malawi.
University of North Carolina At Chapel Hill, Chapel Hill, USA.

Anthony Charles (A)

UNC-Project Malawi, Private Bag A-104, Lilongwe, Malawi.
University of North Carolina At Chapel Hill, Chapel Hill, USA.

Clara Lee (C)

UNC-Project Malawi, Private Bag A-104, Lilongwe, Malawi.
Ohio State University, Columbus, USA.

Satish Gopal (S)

UNC-Project Malawi, Private Bag A-104, Lilongwe, Malawi. satish_gopal@med.unc.edu.
University of North Carolina At Chapel Hill, Chapel Hill, USA. satish_gopal@med.unc.edu.

Tamiwe Tomoka (T)

UNC-Project Malawi, Private Bag A-104, Lilongwe, Malawi. tomoka@unclilongwe.org.
University of North Carolina At Chapel Hill, Chapel Hill, USA. tomoka@unclilongwe.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH